RedX Pharma

RedX Pharma logo

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class.

Contact RedX Pharma via their website

News archive

08/03/2019   Redx Pharma CEO Lisa Anson appears in Telegraph feature article...more
14/02/2019   Redx announces promising data for lead ROCK2 compound...more
14/02/2019   Redx announces directorate update and grant of options...more
21/01/2019   Redx to resume RXC004 clinical trial programme...more

30/11/2018   Redx Pharma announces first RXC006 data suggests great fibrosis treatment potential...more
19/11/2018   Redx Pharma appoints Dr James Mead as CFO...more
14/11/2018   Redx Pharma announces new drug development candidate for fibrosis...more
05/11/2018   Redx Pharma presents Preclinical data evaluating RXC004...more
26/10/2018   RedX presents details of ROCK2 inhibitors for the treatment of chronic kidney disease...more
04/09/2018   Redx Pharma Announces Way Forward For RXC004...more
31/05/2018   RedX Pharma joins the BioPartner programme...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code